AzTrials
AzTrials

DepressionNCT05648175

Comparing Clinical Decision-making of AI Technology to a Multi-professional Care Team in ECBT for Depression

A study testing e-CBT, e-CBT + Phone Call and e-CBT + Phone Call + Pharmacotherapy in people with Depression, run by Dr. Nazanin Alavi at 1 site in Canada.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Depression is a leading cause of disability worldwide, affecting up to 300 million people globally. Despite its high prevalence and debilitating effects, only one-third of patients newly diagnosed with depression initiate treatment. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Depression
What is being tested?
e-CBT, e-CBT + Phone Call and e-CBT + Phone Call + Pharmacotherapy
Could I receive a placebo?
No, everyone receives an active treatment
How many people
186 participants
Where
1 siteCanada
Study dates
1 Dec 2022to 1 Dec 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Diagnosed with MDD by a trained research assistant according to the criteria outlined in the DSM-5
  • Ability to provide informed consent
  • Ability to speak and read English
  • Having consistent and reliable access to the internet

Who cannot join

  • Active psychosis
  • Acute mania
  • Severe alcohol, or substance use disorder
  • Active suicidal or homicidal ideation
  • Currently receiving psychotherapy

Trial locations and contacts

1 site in 1 country.

Nazanin Alavi, MD FRCPC contact

613-544-3310

nazanin.alavitabari@kingstonhsc.ca

Canada1 site, 1 recruiting
  • Hotel Dieu Hospital

    Kingston, Ontario, K7L 5G3

    Nazanin Alavi, 6479672079, nazanin.alavitabari@kingstonhsc.ca

    Nazanin Alavi, MD FRCPC

    Recruiting

Other trials in Canada

About this study

Official title: Comparing Clinical Decision-making of AI Technology to a Multi-professional Care Team in an Electronic Cognitive Behavioural Therapy Program for Depression

Depression is a leading cause of disability worldwide, affecting up to 300 million people globally. Despite its high prevalence and debilitating effects, only one-third of patients newly diagnosed with depression initiate treatment. Electronic cognitive behavioural therapy (e-CBT) is an effective treatment for depression and is a feasible solution to make mental health care more accessible. Due to its online format, e-CBT can be combined with variable therapist engagement to address different care needs. Typically, a multi-professional care team determines which combination therapy is the most beneficial to the patient. However, this process can add to the costs of these programs. Artificial intelligence (AI) technology has been proposed to offset these costs. Therefore, this study aims to determine a cost-effective method to decrease depressive symptoms and increase treatment adherence to e-CBT. This will be done by comparing AI technology to a multi-professional care team when allocating the correct intensity of care for individuals diagnosed with depression. This study is a double-blinded randomized controlled trial recruiting individuals (n = 186) experiencing depression according to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5). The degree of care intensity a participant will receive will be randomly decided by either: (1) a machine learning algorithm (n = 93), or (2) an assessment made by a group of healthcare professionals (n = 93). Subsequently, participants will receive depression-specific e-CBT treatment through the secure online platform, OPTT. There will be three available intensities of therapist interaction: (1) e-CBT; (2) e-CBT with a 15-20-minute phone/video call; and (3) e-CBT with pharmacotherapy. This approach aims to accurately allocate care tailored to each patient's needs, allowing for more efficient use of resources.

Read the detailed description

Participants (n = 186: n = 31 per e-CBT group * 2 arms) will be recruited at Queen's University from outpatient psychiatry clinics at both Kingston Health Sciences Centre sites (Hotel Dieu Hospital and Kingston General Hospital), as well as Providence Care Hospital in Kingston, Ontario. Additionally, self-referrals and referrals from family doctors, physicians, and clinicians across Ontario will be accepted. After obtaining informed consent from the participant, the participant will be evaluated using the Mini International Psychiatric Assessment (MINI) through a secure video appointment to confirm a diagnosis of Major Depressive Disorder using the DSM-5 by a trained professional on the research team.

All eligible participants will be randomized to receive a treatment plan based on the decision of either the healthcare team (Arm 1) or the Triage Module using an AI algorithm (Arm 2). Participants will be randomly allocated to one of the two arms of the study by a research assistant on the team who will also balance the group based on demographic variables (i.e., sex, gender, age, and income). Participants and therapists in the study will be blinded to which treatment arm the participant belongs to. By the nature of this study, participants and therapists will not be blinded to which treatment intensity the participant will receive since it will be evident whether the participant is receiving a phone/video call in addition to usual e-CBT care or pharmacotherapy. Each participant will be provided with an effective form of treatment (i.e., e-CBT) regardless of which group they will be allocated to. Participants will be informed that there is no incentive for joining the program and that joining or withdrawing at any point will not affect them negatively. It will also be explained to the participants that the program is not a crisis resource and that they will not always have access to their therapists. In the case of an emergency, participants will be directed to proper resources, and this event will be reported to the study's lead psychiatrist (principal investigator). All data will be anonymized and will be analyzed by members of the research team who are not directly involved in the patient's care.

Treatment Arm 1: Healthcare Team Allocation

Allocation of treatment intensity by the multi-professional healthcare team will be based on the following criteria:

  1. The severity of MDD symptoms (using DSM-5 criteria).
  2. Mental health factors (prior treatments and responses, current and past psychotic/manic episodes, current and past suicidal/homicidal ideation/attempts, family mental health history, past psychiatric history, and hospital admissions).
  3. Medical factors (current medical conditions and medications, personal and family medical history).
  4. Social factors (support system and living situation, and occupational, social, and personal functional impairment).

Additionally, to assess the severity of MDD symptoms and the functional impairments, participants will complete the PHQ-9 and Sheehan Disability Scale (SDS) before the assessment appointment. The assessment appointment will be conducted by the trained research assistant on the multidisciplinary team who will relay the information to the rest of the team later to deliberate on treatment intensity allocation. All assessments will occur virtually through phone and video calls. Together, the healthcare team will decide whether the participant should be assigned to the e-CBT-only treatment, e-CBT treatment with weekly phone/video calls, or e-CBT treatment with pharmacotherapy. This process mimics the current triage process in clinical settings. To track cost-effectiveness, the trained research assistant will track the total duration of the individual assessment and team deliberation meetings for analysis of the total time commitment per patient.

Treatment Arm 2: AI Algorithm Allocation Allocation of treatment intensity by the proposed AI algorithm will be based on the machine learning and natural language processing (NLP) of textual data provided by participants and their PHQ-9 score collected through a pre-treatment screening module called the Triage Module. This module, developed by the research team, (1) provides psychoeducation on the effects of psychotherapy, (2) collects PHQ-9 scores, and (3) asks participants six open-ended questions regarding their mental health history, their experiences with mental health disorders, and what mental health difficulties they are currently facing. Based on the participant's answers to the open-ended questions, a variable called "Symptomatic Score" will be calculated using the NLP algorithm. If the PHQ-9 score < 19 and the Symptomatic Score > 0.75, the participant will be assigned to the e-CBT-only treatment group. However, if either the PHQ-9 score is > 19 or the Symptomatic Score is < 0.75, the participants will be assigned to the e-CBT treatment with weekly phone/video calls. If both scenarios occur and the PHQ-9 > 19 and Symptomatic Score < 0.75, then the participant will be assigned to the e-CBT treatment with pharmacotherapy.

To gather the relevant data (i.e., participant compliance and change in depression severity, as evaluated by the PHQ-9), the triage module was designed. As previously explained, NLP of the participants' written accounts of their challenges with depression in the Triage Module will be used to calculate a Symptomatic Score. To verify the AI's treatment allocation logic, the completion rate and the change in PHQ-9 scores were assessed in a sample of participants (n = 190) who were previously enrolled in e-CBT-only treatment. The decision-making algorithm determined that the e-CBT-only program was suitable for 62 out of the 190 participants (33%). Within these 62 participants, 54% had completed the e-CBT-only program in its entirety and only 20% had a final PHQ-9 score > 14. Furthermore, the algorithm indicated that e-CBT with telephone calls would be suitable for 100 out of the 190 participants (53%). Of the 100 participants, 41% completed the whole round of e-CBT-only therapy and 31% had a final PHQ-9 score > 14. Lastly, the algorithm indicated that e-CBT with video call was appropriate for 28 out of 190 participants (14%). Of these 28 participants, 35% completed the whole round of e-CBT-only therapy and 40% had a final PHQ-9 score > 14. The logic of the AI's decision is therefore justified as those participants allocated to the e-CBT-only group had the highest percentage of completion and lowest percentage of final PHQ-9 scores > 14 when completing e-CBT-only. Therefore, these individuals require minimal therapist intensity, and e-CBT-only is sufficient. Conversely, participants allocated to the e-CBT with video call had the lowest completion rates and highest rates of final PHQ-9 scores > 14 when enrolled in e-CBT-only. These findings justify the AI's logic that greater therapist interaction is required. It is also important to note that demographic factors like age (below or above 40 years), sex (male or female) and income (less or more than $50K) did not have any significant effects on the number of sessions completed by participants (p = 0.92, 0.18 \& 0.9 for age, sex, and income respectively). The demographic factors did not affect the change in PHQ-9 score (i.e., the difference between the beginning and end of treatment scores) either (p = 0.2, 0.46 \& 0.39 for age, sex, and income respectively).

e-CBT Program The e-CBT sessions used in this study include content based on cognitive restructuring and behavioural activation techniques. The purpose of the sessions is to help participants become aware of inaccurate or negative thinking patterns so that they can view challenging situations more clearly and respond to them effectively. The sessions prompt participants to understand their situation/environment and the resulting thoughts, behaviours, physical reactions, and feelings. The goal of this program is to help change participants' negative and/or ineffective thoughts to more effective ways of thinking. As expressed in CBT, changing thoughts can subsequently affect feelings, behaviours, and physical reactions to stressful situations.

Therapists Each participant will be assigned a care provider that will provide feedback for their weekly sessions before the start of their next session. The assigned care provider will be independent of the multi-professional healthcare team that conducted the intake assessment. All care providers are trained in psychotherapy and have experience delivering electronic psychotherapy. They will be informed of the aim and the content of each therapeutic session. They will also continue receiving specialized training through webinars, workshops and exercises with feedback provided by the lead psychiatrist on the research team, a trained and licensed psychotherapist. All care providers will be supervised by a trained psychotherapist and the lead psychiatrist, and all feedback will be reviewed before submission to the participants.

e-CBT Weekly Feedback Weekly homework is reviewed by the independent care provider assigned to the participant, who will provide text-based personalized feedback on OPTT before the next weekly session. Additionally, the participants and care providers can communicate asynchronously on OPTT to relay any questions or concerns. The care providers will be provided with sample feedback templates and scripts for the telephone and video call sessions. Templates and scripts will be adapted from previous studies conducted by the research team. Feedback templates and scripts will vary between sessions, and care providers will personalize them for each patient. The feedback templates follow a generic structure starting with, acknowledging the participant's time and effort since the last session, summarising the CBT concepts taught in the previous session, reviewing the event they explained in their homework, validating the participant's experience(s), and encouraging the participant to keep up with the sessions. The feedback is written in a letter format to increase personalization and build rapport with the participants.

Conditions
Depression
Being tested
e-CBT, e-CBT + Phone Call, e-CBT + Phone Call + Pharmacotherapy
Medical subject headings
Depression

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • e-CBTBehavioural

    The participant will submit their weekly homework and receive personalized feedback from their assigned therapist on OPTT. The feedback adds customization by acknowledging the participant's experiences in the past week and ensures the participant has understood the CBT concepts.

  • e-CBT + Phone CallBehavioural

    In addition to the e-CBT program (see 1 above), the participant will receive a weekly phone/video call from their assigned therapist. The goal is to build on the therapeutic relationship and to add personalization with direct verbal encouragement. This phone/video call is limited to a one-time, 15-20 minutes call each intervention week.44 The purpose is to check with the patient on their treatment progress. The secure call will either be a phone or video (via Microsoft Teams) call, depending on the preference of the patient.

  • e-CBT + Phone Call + PharmacotherapyBehavioural

    In addition to the e-CBT program (see 1 above), the participant will receive standard pharmacotherapy following DSM-5 guidelines. A pharmacotherapy allocation system has been developed (Figure 1; Figure 2) that follows clinical guidelines. All medications will be prescribed by a psychiatrist on the research team. All medications are a part of the clinical standard of care. The medications will be provided to the participant through the normal process of receiving medication (i.e., pharmacy). Participants allocated to the e-CBT + Phone Call + Pharmacotherapy arm will begin the pharmacotherapy optimization process at the same time as they begin the e-CBT program. Oversight of medication in the e-CBT + Pharmacotherapy arm will be conducted by a psychiatrist on the team who will make a judgement regarding whether to alter the medications. This will not require any additional study visits/time commitment for the participants in this arm.

Study groups in NCT05648175
Study groupRoleWhat they receive
Artificial Intelligence AllocationExperimentalAllocation of treatment intensity by the proposed AI algorithm will be based on the machine learning and natural language processing (NLP) of textual data provided by participants and their PHQ-9 score collected through a pre-treatment screening module called the Triage Module. This module, developed by the research team, (1) provides psychoeducation on the effects of psychotherapy, (2) collects PHQ-9 scores, and (3) asks participants six open-ended questions regarding their mental health history, their experiences with mental health disorders, and what mental health difficulties they are currently facing. Based on the participant's answers to the open-ended questions, a variable called "Symptomatic Score" will be calculated using the NLP algorithm.
Receives: Behavioral: e-CBT; Behavioral: e-CBT + Phone Call; Behavioral: e-CBT + Phone Call + Pharmacotherapy
Healthcare Team AllocationActive comparatorAllocation of treatment intensity by the multi-professional healthcare team will be based on the following criteria: 1. The severity of MDD symptoms (using DSM-5 criteria). 2. Mental health factors (prior treatments and responses, current and past psychotic/manic episodes, current and past suicidal/homicidal ideation/attempts, family mental health history, past psychiatric history, and hospital admissions). 3. Medical factors (current medical conditions and medications, personal and family medical history). 4. Social factors (support system and living situation, and occupational, social, and personal functional impairment).
Receives: Behavioral: e-CBT; Behavioral: e-CBT + Phone Call; Behavioral: e-CBT + Phone Call + Pharmacotherapy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Patient Health Questionnaire (PHQ-9) Score

    Scale of 0-3 per question, 0 = not at all, 3 = nearly every day, higher score = worse

    Measured: week 0, 4, 7, 10, 13, and 3, 6, and 12-month follow-up.

  2. Change in Quick Inventory of Depressive Symptoms (QIDS) Score

    Scale of 0-3 per question, 0 = better, 3 = worse

    Measured: week 0, 4, 7, 10, 13, and 3, 6, and 12-month follow-up.

  3. Change in Assessment of Quality of Life (AQoL-8D) Score

    Scale of 0-5 per question, 0 = better, 5 = worse

    Measured: week 0, 4, 7, 10, 13, and 3, 6, and 12-month follow-up.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Dec 2022
  2. Study start1 Dec 2022
  3. Primary completion1 Dec 2025 (estimated)
  4. Study completion1 Dec 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
If eligible for this randomized controlled trial, participants (n = 186) will be randomized to receive an e-CBT treatment recommended by a multi-professional healthcare team consisting of a psychiatrist, psychiatric medical resident, and a trained research assistant (Arm 1, control group; n = 93), or the AI machine learning algorithm (Arm 2, experimental group; n = 93).
Masking
Double blind
Who is masked
Care provider, Investigator
Enrolment
186 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05648175
Sponsor's protocol ID
6037580
Status last verified
Oct 2024
First submitted
5 Dec 2022
Last updated
18 Oct 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Open-access publication

Questions about this trial

What is this clinical trial studying?

A study testing e-CBT, e-CBT + Phone Call and e-CBT + Phone Call + Pharmacotherapy in people with Depression, run by Dr. Nazanin Alavi at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 18 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Nazanin Alavi, MD FRCPC (613-544-3310, nazanin.alavitabari@kingstonhsc.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Patient Health Questionnaire (PHQ-9) Score (time frame: week 0, 4, 7, 10, 13, and 3, 6, and 12-month follow-up.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Oct 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in